At the news
? MIXEDIMPACT 4/10 8-K filed May 4, 2026 at 16:10 ET
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.7%, as R&D spending increased to $31.4M. However, the company announced selection of rinzimetostat RP3D and positive clinical data, with cash of $419.7M funding operations into 2H 2028.
- Net loss per share $(0.34) vs consensus $(0.31) (EPS miss of ~9.7%)
- Q1 2026 net loss $35.8M vs $30.0M in Q1 2025, driven by higher R&D costs
- Cash, cash equivalents and investments $419.7M as of March 31, 2026
- R&D expenses $31.4M, up 27.5% YoY due to advancement of rinzimetostat and enozertinib
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access